Knott David M Jr Acquires 96,786 Shares of Day One Biopharmaceuticals, Inc. $DAWN

Knott David M Jr boosted its holdings in shares of Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) by 287.1% during the third quarter, Holdings Channel.com reports. The firm owned 130,500 shares of the company’s stock after acquiring an additional 96,786 shares during the period. Knott David M Jr’s holdings in Day One Biopharmaceuticals were worth $920,000 at the end of the most recent reporting period.

Other institutional investors have also bought and sold shares of the company. Franklin Resources Inc. grew its stake in shares of Day One Biopharmaceuticals by 2.0% in the 2nd quarter. Franklin Resources Inc. now owns 4,097,625 shares of the company’s stock worth $26,635,000 after buying an additional 79,255 shares in the last quarter. Vestal Point Capital LP raised its position in shares of Day One Biopharmaceuticals by 15.5% during the 2nd quarter. Vestal Point Capital LP now owns 3,000,000 shares of the company’s stock valued at $19,500,000 after buying an additional 401,873 shares in the last quarter. Geode Capital Management LLC raised its position in shares of Day One Biopharmaceuticals by 11.2% during the 2nd quarter. Geode Capital Management LLC now owns 1,712,429 shares of the company’s stock valued at $11,132,000 after buying an additional 171,964 shares in the last quarter. Goldman Sachs Group Inc. lifted its holdings in shares of Day One Biopharmaceuticals by 232.4% in the 1st quarter. Goldman Sachs Group Inc. now owns 1,569,918 shares of the company’s stock valued at $12,449,000 after acquiring an additional 1,097,679 shares during the last quarter. Finally, AIGH Capital Management LLC bought a new position in shares of Day One Biopharmaceuticals in the 3rd quarter valued at about $10,719,000. Institutional investors own 87.95% of the company’s stock.

Wall Street Analysts Forecast Growth

DAWN has been the topic of a number of recent research reports. JonesTrading restated a “hold” rating and set a $21.50 price objective (up from $20.00) on shares of Day One Biopharmaceuticals in a research report on Friday. Oppenheimer reissued a “market perform” rating on shares of Day One Biopharmaceuticals in a research report on Friday. Zacks Research lowered Day One Biopharmaceuticals from a “strong-buy” rating to a “hold” rating in a report on Wednesday, February 25th. HC Wainwright lowered their price target on Day One Biopharmaceuticals from $25.00 to $22.00 and set a “buy” rating for the company in a research report on Wednesday, February 25th. Finally, Needham & Company LLC reiterated a “hold” rating on shares of Day One Biopharmaceuticals in a research report on Friday. Four investment analysts have rated the stock with a Buy rating, six have given a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, Day One Biopharmaceuticals presently has a consensus rating of “Hold” and an average target price of $25.56.

Day One Biopharmaceuticals Price Performance

Shares of NASDAQ DAWN opened at $21.20 on Friday. Day One Biopharmaceuticals, Inc. has a 1 year low of $5.64 and a 1 year high of $21.23. The firm has a 50-day simple moving average of $11.10 and a two-hundred day simple moving average of $9.05. The company has a market cap of $2.19 billion, a P/E ratio of -20.58 and a beta of -1.25.

Day One Biopharmaceuticals (NASDAQ:DAWN) last released its earnings results on Tuesday, February 24th. The company reported ($0.21) EPS for the quarter, missing analysts’ consensus estimates of ($0.17) by ($0.04). Day One Biopharmaceuticals had a negative net margin of 67.85% and a negative return on equity of 23.43%. The business had revenue of $53.72 million for the quarter, compared to the consensus estimate of $49.81 million. As a group, equities research analysts expect that Day One Biopharmaceuticals, Inc. will post -0.72 EPS for the current year.

Insider Buying and Selling

In other Day One Biopharmaceuticals news, insider Lauren Merendino sold 5,814 shares of the stock in a transaction on Tuesday, February 17th. The stock was sold at an average price of $11.60, for a total value of $67,442.40. Following the sale, the insider owned 60,157 shares in the company, valued at $697,821.20. This trade represents a 8.81% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, CFO Charles N. York II sold 6,065 shares of Day One Biopharmaceuticals stock in a transaction on Tuesday, February 17th. The stock was sold at an average price of $11.60, for a total value of $70,354.00. Following the sale, the chief financial officer owned 312,025 shares of the company’s stock, valued at approximately $3,619,490. This trade represents a 1.91% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold a total of 36,461 shares of company stock worth $422,948 over the last ninety days. Corporate insiders own 6.20% of the company’s stock.

Key Day One Biopharmaceuticals News

Here are the key news stories impacting Day One Biopharmaceuticals this week:

• Positive Sentiment: Acquisition announced — Servier agreed to buy Day One for $21.50 per share in cash (~$2.5 billion), a deal that crystallizes a takeover premium and explains the sharp rally; the transaction is subject to customary closing conditions and is expected to close in Q2 2026. Article Title
• Positive Sentiment: Analyst target raised — JonesTrading reiterated a “hold” but increased its price target to $21.50 (from $20.00), putting its target in line with the buyout price and reinforcing the deal valuation. Article Title
• Positive Sentiment: Options and volume spike — Unusual call-option activity and extremely high trading volume point to takeover-driven speculative buying and arbitrage interest ahead of the deal close (increased open interest and buy-side activity tend to amplify intraday moves).
• Neutral Sentiment: Trading halt — Shares were temporarily halted earlier for “News pending,” a standard market pause when material corporate announcements are imminent; this is procedural and common around M&A.
• Neutral Sentiment: Ratings reaffirmed — Needham and JonesTrading reaffirmed their “hold” ratings (Needham also maintained its view) even as price targets moved; these keep analyst sentiment mixed despite the takeover. Article Title
• Negative Sentiment: Multiple shareholder investigations and potential litigation — Several law firms (e.g., Brodsky & Smith, Ademi LLP, Halper Sadeh, Monteverde & Associates) announced probes into whether the Board obtained a fair price and followed a proper process; lawsuits or injunctions could delay closing, increase deal costs, or put pressure on the eventual net proceeds to shareholders. Article Title Article Title

Day One Biopharmaceuticals Company Profile

Day One Biopharmaceuticals, Inc (NASDAQ: DAWN) is a clinical-stage biopharmaceutical company focused on the discovery and development of targeted therapies for oncology. The company employs a precision medicine approach, leveraging biomarker-driven strategies to identify patient populations most likely to respond to its investigational compounds. By concentrating on well-validated molecular drivers of cancer, Day One seeks to deliver first-in-class or best-in-class therapies with the potential for meaningful clinical benefit.

The company’s pipeline includes several small-molecule candidates in various stages of development.